Lumateperone (Caplyta) Discontinuation Schedule
Caplyta (lumateperone) is dosed as 42 mg once daily for schizophrenia in adults. [1]
Caplyta labeling states that the dose should not be changed and the medication should not be stopped without first talking to the healthcare provider. [2]
A dosing strategy such as every-other-day administration for tapering while continuing risperidone and clonazepam is not a labeled or established regimen. [1][2]
Usual Dosing and Pharmacokinetics
The recommended Caplyta dosage for schizophrenia is 42 mg orally once daily with or without food. [1]
Lumateperone has an approximate terminal half-life of ~18 hours after intravenous administration, which implies that dosing every other day would substantially lower steady exposure compared with once-daily dosing. [3]
Evidence for Alternate-Day Tapering
No clinical-trial or label-supported regimen is provided for alternate-day tapering of lumateperone. [1][2]
Discontinuation is therefore expected to be individualized by the prescribing clinician based on symptom stability and relapse risk rather than a fixed alternate-day schedule. [2]
Concomitant Risperidone and Clonazepam
Caplyta labeling provides dosing guidance for lumateperone independent of concomitant antipsychotic or benzodiazepine use. [1]
No published, label-supported discontinuation schedule is provided that specifically addresses every-other-day Caplyta tapering while continuing risperidone and clonazepam. [1][2]
Clinical Safety and Monitoring During Changes
Because sudden stopping or unsupervised dose reduction is cautioned against in the labeling, symptom recurrence or relapse can occur when changes are made without prescriber guidance. [2]
Sedation, dizziness, and orthostatic hypotension risk can occur with lumateperone, which can complicate assessment during dose changes. [1]
Practical Recommendation for Medication Changes
Caplyta should not be tapered using an alternate-day schedule unless explicitly directed by the prescribing clinician. [2]
Any planned discontinuation should be coordinated with the clinician managing schizophrenia while maintaining or adjusting risperidone and clonazepam as clinically indicated. [2]